Relay Therapeutics, Inc.
A clinical-stage biotechnology company in Cambridge, Massachusetts, that designs small-molecule medicines by studying how proteins move and change shape, using its Dynamo platform to create "movies" of protein motion rather than static snapshots. Founded in 2015 as Allostery, Inc., it was renamed Relay Therapeutics to reflect that focus on protein motion, and its lead drug candidate targets a common mutation in breast cancer.
Sold 6.00M
Granted 994 · Sold 105.2K
Granted 93.5K · Sold 147.4K
Granted 994 · Sold 54.3K
Granted 171.2K · Sold 280.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| SB Investment Advisers (Uk) LTD +2 co-filers10% owner · 1 transaction | — | 21.90M | — | — | 6.00M |
| Patel SanjivPresident and CEO, Director · 3 transactions | -3.9% | 3.00M | 994 | — | 105.2K |
| Bergstrom Donald APresident, R&D · 6 transactions | -7.4% | 512.0K | 93.5K | — | 147.4K |
| Rahmer PeterSee remarks · 6 transactions | -27% | 275.9K | 994 | — | 54.3K |
| Catinazzo ThomasChief Financial Officer · 16 transactions | -47.1% | 177.5K | 171.2K | — | 280.3K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -6.59M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.